On November 20, Gelonghui reported that Sichuan Kelun Pharmaceutical (002422.SZ) stated on the investor interaction platform that its subsidiary Kelun Botai has signed an exclusive license agreement with the Affiliated Hospital of Southwest Medical University regarding the radioactive nuclide drug conjugate TBM-001, and has initiated the collaborative development of other RDC drugs to address unmet clinical needs, besides TBM-001.
科伦药业(002422.SZ)：子公司科伦博泰与西南医科大学附属医院就放射性核素药物偶联物TBM-001已订立独占性许可协议
Sichuan Kelun Pharmaceutical (002422.SZ): The subsidiary Kelun Botai has signed an exclusive licensing agreement with the Southwest Medical University Affiliated Hospital for the radiolabeled drug conjugate TBM-001.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated